Patents by Inventor Guillaume DECORET

Guillaume DECORET has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MALONITRILE DERIVATIVES
    Publication number: 20230242494
    Abstract: The invention relates to a compound of formula (I) wherein R1-R4 and A1-A2 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 18, 2021
    Publication date: August 3, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Guido GALLEY, Katrin GROEBKE ZBINDEN, Nicole GROSSMANN, Wolfgang GUBA, Daniel HUNZIKER
  • MALONITRILE DERIVATIVES
    Publication number: 20230242520
    Abstract: The invention relates to a compound of formula (I) wherein R1-R2 are as defined in the description and in the claims The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 18, 2021
    Publication date: August 3, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guillaume DÉCORET, Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Daniel HUNZIKER
  • TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM
    Publication number: 20230135093
    Abstract: The invention provides compounds having the general formula (I) or (II) wherein R1, R2, R3, X, Y and Z are as described herein, compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 11, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Giuseppe CECERE, Guillaume DÉCORET, Katrin GROEBKE ZBINDEN, Maria-Clemencia HERNANDEZ, Henner KNUST, Andreas KOBLET, Andres Miguel OLIVARES MORALES, Emmanuel PINARD, Valerie RUNTZ-SCHMITT
  • HETEROCYCLIC COMPOUNDS AS INHIBITORS OF MONOACYLGLYCEROL LIPASE (MAGL)
    Publication number: 20220135591
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein R1 to R7, A, L1, and RA1 to RA3 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Application
    Filed: October 8, 2021
    Publication date: May 5, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Guillaume DECORET, Uwe GRETHER, Katrin GROEBKE ZBINDEN, Benoit HORNSPERGER, Bernd KUHN, Hans RICHTER, Didier ROMBACH, Fionn O'HARA, Carsten KROLL
  • 2-AMINOOXAZOLINES AS TAAR1 LIGANDS
    Publication number: 20100311798
    Abstract: The invention relates to compounds of formula wherein R1, R2, R2?, X, Y, andn are as defined in the specification or to a pharmaceutically suitable acid addition salt thereof. The compounds of formula I are active on the TAAR1 receptor and are therefore suitable for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders, schizophrenia, neurological diseases, Parkinson's disease, neurodegenerative disorders, Alzheimer's disease, epilepsy, migraine, substance abuse and metabolic disorders, eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.
    Type: Application
    Filed: May 28, 2010
    Publication date: December 9, 2010
    Inventors: Guillaume Décoret, Guido Galley, Katrin Groebke Zbinden, Roger Norcross